| 1. | | Recruiting | 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ... |
| 2. | | Recruiting | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
Conditions: recurrent bladder cancer; stage IV bladder cancer; metastatic transitional cell cancer of the renal pelvis and ureter; ... |
| 3. | | No longer recruiting | Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Conditions: stage IV colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; ... |
| 4. | | Recruiting | CCI-779 in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: gastrointestinal carcinoid tumor; Islet Cell Carcinoma; pulmonary carcinoid tumor |
| 5. | | Recruiting | Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: extensive stage small cell lung cancer; Recurrent Small Cell Lung Cancer |
| 6. | | No longer recruiting | Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; refractory chronic lymphocytic leukemia |
| 7. | | Recruiting | Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: adult acute myeloid leukemia; atypical chronic myeloid leukemia; myelodysplastic and myeloproliferative disease; Myelodysplastic Syndromes; ... |
| 8. | | Recruiting | Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Condition: Head and Neck Cancer |
| 9. | | No longer recruiting | Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Conditions: stage IV colon cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer; adenocarcinoma of the colon; ... |
| 10. | | Recruiting | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Conditions: adult solid tumor; Non-small cell lung cancer; Prostate Cancer |
| 11. | | Not yet recruiting | GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
Conditions: adenocarcinoma of the prostate; recurrent prostate cancer |
| 12. | | No longer recruiting | Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
Conditions: recurrent salivary gland cancer; salivary gland adenoid cystic carcinoma; stage III salivary gland cancer; stage IV salivary gland cancer |
| 13. | | Not yet recruiting | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Conditions: high-grade salivary gland carcinoma; low-grade salivary gland carcinoma; Salivary Gland Cancer |
| 14. | | Not yet recruiting | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
Conditions: recurrent prostate cancer; stage IV prostate cancer |
| 15. | | Recruiting | Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Conditions: adult primary hepatocellular carcinoma; advanced adult primary liver cancer; localized unresectable adult primary liver cancer; ... |
| 16. | | Suspended | Perifosine in Treating Patients With Advanced Pancreatic Cancer
Conditions: recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; stage II pancreatic cancer; adenocarcinoma of the pancreas; ... |
| 17. | | Recruiting | Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer
Conditions: Male Breast Cancer; recurrent breast cancer; stage IV breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer |
| 18. | | Not yet recruiting | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Oropharyngeal Cancer; paranasal sinus and nasal cavity cancer; ... |
| 19. | | Recruiting | Tipifarnib in Treating Patients With Recurrent Bladder Cancer
Conditions: recurrent bladder cancer; stage 0 bladder cancer; stage I bladder cancer; transitional cell carcinoma of the bladder |
| 20. | | Completed | UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: peritoneal cavity cancer; recurrent ovarian epithelial cancer; Fallopian Tube Cancer |
| 21. | | Recruiting | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer; ... |
